UNITED STATES ENVIRONM ENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

MEMORANDUM DATE: October9, 2014 OFFIC E OF CHEMICAL SAFETY AND POLLUTION PREVENTION

SUBJECT: Oxyfluorfen : Human Health Asse ssment Scoping Document in Support of Registration Review
. PC Code: I I 1601 Decision No.: 489866 Petition No.: NA Risk Assessment T ype : NA TXRNo.:NA MRIDNo.: NA DP Barcode: 0419418 Regis tration No.: NA Regulatory Action: Registration Review Scoping Case No.: 2490 CAS No.: 42874

- 03-3 40 CFR: § 180.38 I
FROM: Ivan D. Nieves, Chemist/Ri sk As ses sor 4 Ayaad Assaad, Ph
.D., Toxicologist , 7

**..9~** Marquea D. Ki ng , Ph. D , Toxicologi

**~;q___** Bonnie Cropp-Kohlligian, Environmental Scientisy Susan Hummel , Chemist Risk Asses sment Branch IV Health Effe cts Division (7509P) THROUGH: Eli ssa Reaves , Ph.D., Branch



# Chi **efc£ ~** **~** Risk Assessment Branch IV Health Effects Divi s ion (75 09P) TO: Benjamin Askin, Chemical Review Manager (RM 51) Risk Management and Implementati on Branch IV Pesticide Re-Evaluation Division (7508P) Attached is the Health Effects Division' s (H ED ) human health scoping document for oxyfluor fe n to support the Registration Review process.

Page 1 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support of Registration Review
Executive Summary The Health Effects Division (HED) has evaluated the status ofthe human health risk assessment for oxyfluorfen to determine the scope of work necessary to support Registration Review. The most recently completed human health risk assessment (2002; Registration Eligibility Decision [RED] 1) was considered as part ofthis seeping exercise. Oxyfluorfen [2-chloro

- 1

- (3

-ethoxy-4-nitrophenoxy)

-4

- (trifluoromethyl) benzene] is a broad spectrum pre- and post-emergent herbicide used to control annual broadleaf and grassy weeds in corn, cotton, soybeans, fruit, nut trees, and ornamentals. It is registered for residential use as a spot treatment to kill weeds on patios , driveways and similar areas. U.S. permanent tolerances for residues of oxyfl uorfen are established under 40 CFR 

### § 180.381 in/on a number of crop and livestock raw agricultural commodities. Formulations include emulsifiable liquid products for agricultural use and granular products for commercial nursery use. Residential products are available as Ready to Use (RTU) trigger sprayer, RTU sprinklerjug or as a liquid to be applied in a sprinkler can or hand-carried tank sprayer. Liquid formulations are applied using groundboom, right-of-way and backpack sprayers. Granular oxyfluorfen might be applied with broadcast spreaders, belly grinder, and handheld equipment. The toxicity database for oxyfluorfen is adequate to support existing registrations and
· Registration Review with the exception ofthe subchronic dermal toxicity study in rabbit which is

required (TXR # 0057003). A database uncertainty factor of 1 OX will be retained for all dermal assessments until this requirement is met. Further, the Hazard and Science Policy Council (HASPOC) concludled that acute and subchronic neurotoxicity studies are not required. All previous doses for risk assessment purposes were assessed with uncertainty factors of 1 OX for interspecies extrapolation and 1OX and intraspecies variability. An additional uncertainty factor of 3X was applied to intermediate-term dermal , inhalation, and incidental-oral exposures because this dose was derived from a LOAEL rather than a NOAEL. An oral endpoint was selected for both the dermal and inhalation exposure. Oxyfluorfen is classified as "Likely to be Carcinogenic to Humans" [Q1* 

## = 7.32 x 10·2 (mg/kg/day)" 1 ). During registration review, endpoint selection, points of departure (PODs) , and uncertainty factors (UFs)/ safety factors (SFs) for the risk • assessments will be re-evaluated based upon updated policies and procedures. The residue chemistry database is adequate. Residue chemistry data submitted since the RED will need to be evaluated and a tolerance for residues of oxyfluorfen in/on cotton gin byproducts may be established. There are no maximum residue limits (MRLs) for residues of oxyfluorfen by Codex or Mexico. Excluding Canadian MRLs with no U.S. equivalent, the remaining Canadian MRLs are fully harmonized with U.S
. tolerances. An acute dietary risk assessment was not conducted because no appropriate endpoint attributable to a single dose was identified. There are no chronic dietary (food and water) risk estimates of concern for oxyfluorfen and its metabolites
. A cancer dietary (food only) risk assessment

1 http: //www.epa.gov/oppsrrdl/reregistrationloxyfluorfenl Page 2 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support of Reg istration Review determined a risk estimat e of3.8 x 10·7 for the general U.S. population. Updated dietary exposure assessments ma y be necess ary under registration review ifthere are sign ificant changes to the drinking water estima ted concentrations which will be updated by EFED , or if there are significant changes to the POD s or UFs / SFs . The most current residential risk assessment did not identify ri sks of concern2

. However, updates to HED 's Residential SOPs3 (2012) have been made along with policy changes for body weight assumptions. Therefore, the residential exposure risk assessment will need to be updated according to current policies during Registration Review. The need for spray drift and volatilization risk assessments for oxyfluorfen will also be examined during the Registration Review process. There are no current aggregate risks est imates of concern for oxyfluorfen. During registration review, updated aggregate assess ments may be conducted as required to include any significant change tha t might occur for toxicological POD s , FQPA and uncertainty factors , dietary exposure estimates , or est imated drinking water concentra tions (EDWCs). The previous occupational exposure asse ssment3 covered all scenarios relevant to oxyfluorfen and no occupational handler or post-application risk estimates of concern were identified with use of appropriate personal protective equipment (PPE) (i.e. , label required chemica l-resistant gloves)
. Registration Review will include an updated handler and post application risk est imat es based on curr ent policies, new toxicolo gy data (a subchronic dermal toxicity study is required) , and required bulb vegetables Dis lodgeable Foli ar Residue (DFR ) data. Chemical 

### Use Profile Oxyfluorfen [2-chloro-1- (3

- ethoxy-4-nitrophenoxy)-4

- (trifluoromethyl) benzene] is a broad spectrum pre- and postemergence herbicide registered for use on a variety of field crops, vegetable s, and fruit tree s and is used to control certain broadleaf and grassy weeds. Oxyfluorfen is a dipheny l ether herbicide structurally related to lactofen and acifluorfen. The diphenyl ether herbicides act by inhibiting protoporphyrinogen oxidase which is the second-tolast enzyme in chlorophyll bi osynthesis in plants and in heme synthesis in animals. The diphenyl ethers are also oncogenic in roden ts . Agricultural uses include control of weeds in field/row crops, orchard floo rs, vineya rd floors, and container and field grown orname ntals. In the residential environment, it is used to kill weeds on paved surfaces such as driveways, patios and sidewalks. Major uses include grapes, almonds, cotton, bulb vegetables , artichokes and pasture/rangeland. Formulations include emulsifiable liquid products for agricultural u se and granular products for commercial nursery u se. Residential products are available as Ready to Use (RTU) trigger sprayer, RTU sprinkler jug or as a liquid to be applied in a spr inkler can or hand -carried tank sprayer. The applicatio n rate s for the oxyfluorfen products range from 0.25 to 2.0 lb s a i per acre per appl ica tion and one or two applications are typically made in the growing season. Liquid formu la tions might be applied using groundboom, airblast, chemigation, aerial and handheld sprayers. Aerial application is

2 Oxyfluorfen : Second Revi sed Occupat ional and Residential Non-Cancer and Cancer Exposure and Risk Assessments for the Reregistration Eligibi lity Decision (RED) Document. T
. Dole. 05/01 /2002
. 0281831 3 Available: http ://www. epa.gov /pestic ides/science /residentia l-exposure- sop . html
Page 3 of20Oxytluorfen: Human Health Risk Assessment Scoping Document in Support of Registration Review used only for fallow fields and chemigation is used primarily for bulb vege tables. Granular oxyfluorfen is ap plied to ornamentals with broadcast spreaders. The nomenclature and physiochemical properties of oxyfluorfen are presented in Tables 1 and 2

of Attachment 1. Hazard Identificationffoxicology The toxicity database for oxyfluorfen is adequate to support existing registrations and registration review with the exce ption of acute and subchronic neurotoxicity stu dies, a s ubchronic dermal toxicity study, and an inhalation toxicity study that was waived (0282729). The Hazard and Science Policy Cou ncil (HASPOC) concluded that the acute and s ubchronic neurotoxicity st udie s are not required, however; the subchronic dermal toxicity study in rabbit is required (TXR # 0057003). A 1 Ox database uncertainty factor is retained for t he dermal route until the dermal study is subm itted and evaluated for ri sk assessment. Oxyfluorfen is of low acute toxicity for acute oral, dermal, and inhalation toxicity (toxicity catego ry IV) . It is a slight eye and dermal irritant and is not a dermal sensitizer. Oxyfluorfen was rapidly absorbed orally, extensively metabolized, and rapidly eliminated. Most of the compound was eliminated in the feces; females eliminated more in the urine t han d i d males. A dermal absorption factor of 18% was selected from a rat dermal absorption study. The liver is the target organ for oxyfluorfen, which is observed as increased liver weight, histopathology, and in crease d liver enzymes throughout the database in all species and studies regardless of the duration or route of exposure. Other toxicological effects include: decreased body weights, increased urine production and water consumption, sligh t anemia, changes in hematological parameters and clinical chemistries, increases in kidney weights, and histopathological observa t ions. Mortality was seen at the hi ghest dose tested in oral subchronic studies. Based upon the developmental and rep roductiv e toxicity s tudi es **review~d,** there does not appear to be a ny increased susceptibility in animals due to pre- or postn atal exposure to oxyfluorfen. The 1 Ox Food Quality Protection Act (FQPA) Safety Factor (SF) for the protection of infants and · children has been reduced to 1 x for the following reasons: ( l ) there is no indication of quantitative or qualitative increased susceptibility of rats or rabbits to in utero and/or postnatal exposure; (2 ) a developmental neurotoxicity study (DNT) with oxyfluorfen is not required ; and (3) the dietary (food and drinking water) and non-di etary (residential) exposure assessments will not underestimate the potential exposures for infants and c hildre n. Oxyfluorfen is classified as "L ikely to be Carcinogenic to Humans" based on the occurrence of treatme nt -re l ated hepato cellular tumors in male mice and the lack of an adequate carcinogenicity

study in a second spec i es. Although there were no mutagenic concerns for oxyfluorfen, the data were inadequate to support a non-mutageni c mode of action for l iver tumorigenes is. The Cancer Peer Review Committee recommended retainin g a linear , l ow dose extrapolation for human risk assessments with a Q1* of7.32 x 10- 2 (mg/kg/day)" 1 in human equivalents. Page 4 of20Oxyfluorfen : Human Health Risk Assessment Scoping Document in Support of Registration Review The acute, subchronic, and chronic toxicity profile tables for oxyfluorfen are included in Attachment 2. Toxicity endpoints, points ofdeparture (PODs), and uncertainty/safety factors (UF / SFs) were selected for oral, dermal, and inhalation exposure pathways for the Human Health Risk Assessment conducted in 2002 (D281831 ), and these are shown in Attachment 3. Upon review of the toxicology data and consideration of all available data including the open literature, the endpoints for risk assessment and all uncertainty factors may be re-evaluated during registration review to reflect current HED policies. 

### Conclusions: The toxicity database for oxyfluorfen is adequate for assessing potential carcinogenetic , mutagenic , developmental , neurotoxic, imrnunotoxic, and reproductive effects. However, a subchronic dermal rabbit toxicity study is required. During registration review, the endpoints and safety factors for risk assessment may be updated to reflect current policies. 

### Dietary Exposure and Risk Assessment The qualitative nature of the re sidue ofoxyfluorfen in plants and livestock is adequately understood. The oxyfluorfen risk assessment team has determined that oxyfluorfen is the residue of concern for tolerance expression and/or risk assessment in crops, livestock and drinking water. Adequate analytical enforcement methods are available. Banana and cotton gin byproducts field trial data (GLN 860.1500) were submitted in response to the RED. These data will be evaluated during Registration Review and a tolerance for residues of oxyfluorfen inion cotton gin byproducts may be established. C acao bean field trial data ( GLN 860.1500) were al so required in the RED ; however, HE D has re-evaluated the residue chemistry database for oxyfluorfen and will translate available coffee field trial data to support the existing uses of oxyfluorfen on cacao beans (D423251 ). The last dietary risk assessment for oxyfluorfen was conducted for the RED (J. Morales, D275401, July 12, 2001)
. Chronic dietary exposure was assessed for uses existing at that time , as well as two IR-4 petitions (grass grown for seed and strawberries). The dietary risk assessment was conducted using the Dietary Exposure Evaluation Model (DEEMTM , Version 7.73). Anticipated residues were u sed in the analysis and calculated using either Pesticide Data Program (PDP) monitoring data or field trial data. B oth the PDP and field trial data sets were consistent in that they show es sentially all non-detectable residues , with the same limit of detection (0.0 1 ppm). In addition , estimates ofpercent crop treated (% CT) was incorporated into the analysis. The cancer dietary exposure/risk assessment used the following 

### Qt* = 7.32 x 

### to- 2 

### (mglkgldayy 1 • An acute dietary risk asse ssment was not conducted because no appropriate endpoint attributabl e to a single dose was found , and no acute reference dose was established. Chronic dietary (food only) risk estimates for oxyfluorfen were below HED ' s level of concern ( < 100% cP AD) for the U.S. population and all population subgroups based mainly on non-detects from PDP monitoring data and field trials (<1% cPAD for all sub-population). For the cancer dietary (food only) exposure assessment, the risk e stimate for the US population was 3.8 x 10-7

.

Page 5 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support of Registration Re view Water was incorporated into the dietary exposure assessment using drinking water l eve l s of concern (DWLOCs). Comparisons were made between DWLOCs and t he estimated concentrations of oxyfluorfen in surface water and ground water generated via Pes t icide Roo t Zone Model/Exposure Analysis Modeling System (PRZM/EXAMS) and Screening Concentration In GROund Water (SCI-GROW) , respectively. The dietary exposure including water as DWLOCs was not of concern for chronic exposure. Upon com p arison of the cancer DWLOC with the environmental concentrations of oxyfl uorfen es t imated using conservative modeling , the surface water concentration (5.7 ppb) is grea ter than the cancer DWLOC (0.315 ppb ). Thus, there may be a concern for oxyfluorfen residues in surface water. Conclusions: The residue chemistry database is adequate. Data submitted since the RED will need to be evaluated and a tolerance for residues of oxyfluorfen inion cotton gin byproducts may be establ i shed. Updated dietary exposure assessments may be necessary under registration review if there are sign ifi cant changes to the drinking water estimated concentrations which will be updated by EFED , or if there are significant changes to the PODs or UFs / SFs. Residential Exposure The last oxyfluorfen hum a n health risk assessment 4 on residential settings ( i .e. , homeown ers treating weeds on patios , driveways and similar surfaces) was done in 2002 (D28183 1 , F. Fort , 4 / 29/02). Short-term non -cancer risk estimates via the dermal and inhalation routes of exposure were assessed for r es id en tial handlers and r esu lting MOEs did no t fall be low RED's LOC of 100, and therefore not of concern. Cancer estimates ranged from 4x 1 o 8 to 6x 1 o- 7 . Postapplication residential exposure risks from t r eated turf were not quantified si nce labeled application instructions were limited to spot treatments (i .e. , did not include broadcast application to lawns) that were intended t o el im inate grass. Residential bystander exposures resulting from off - site transport (e.g., spray drift or volat ilization ) may occur as a result of applications of oxyfluorfen. The potential for spray drift

will be quantit atively evaluated for each pesticide during the Re gistration Review process which ensures that all uses for that pesticide will be co n s idered concurrently. The approach is outlined in the revised (2012) Standard Operating Procedures for Residen t ial Risk Assessmen t (SOPs)

- Residential Exposure Assessment Standard Operating Procedures Addenda 1: Consideration of Spray Drift. This document outli nes the quantification of indirect non-occupational exposure to

drift. In terms of volatilization , the agency has developed a Volatilization Screening To ol and a subsequent Volatilization Screening Ana l ysis (http: // www. r egulations.gov /# !docket D etail;D = EPA- HQ-OPP- 20 1 4-0219). During Registration Review, the agency will u t ilize this analysis to determine if data ( i.e. , flux studies, route-specific inhalation toxicological studies) or further analysis i s required for oxyfluorfen. Conclusions: The residen t ial exposure risk assessment did not identify risks of concern in 2002. However, updates to HED's Residential SOPs 5 (2012) have been made along with polic y

changes for body weight assumpt ion s. Ther e fore , the residential exposure r i sk assessment wi ll be updated to reflect current policies during Registration Review. Addi t ionally , a subchronic

4 Oxyfluorfen . Revi s ed Human Health Risk Assessment. HED Chapter for the Rere g i s tration Eligibility Deci s ion (RED) , 0281831 , F . Fort , 4 /2 9 / 02 5 Available: http: // www . epa.go v/ pesticides / sc i ence / residential-exposure-sop . html Page 6 of20Oxyfluorfen: Human Health Ri sk Assessment Scoping Document in Support of Regi strat i on Review dermal rabbit toxicity study is required, therefore dermal risk e stimates will need to be updated during Registration Review based on this study. The need for spray drift and volatilization risk assessment for oxyfluorf en will be examined during the Registration Review process as well. 

### Aggregate Risk Assessment In accordance with the Food Quality Protection Act (FQPA), HED must consider and aggregate pesticide exposures and risks from three major sources: food , drinking water, and residential exposures . The aggregate risk assessment evaluates the combined risk from dietary exposure (food and water) and any non-occupational (residential) uses. Acute Aggregate An acute endpoint has not been identified; therefore, an acute aggregate risk assessment is not required. Short-term Aggregate Short-term DWLOCs were calculated based upon average food residue s and re sidential handler exposure. Surface and ground water concentrations estimates using conservative mode ling were below the short-term DWLOC s for oxyfluorfen. Consequently, there was no short-term exposure concern for drinking water from surface or groundwater sources. Chronic Aggregate Since no chronic residential scenarios ha v e been identified, chronic DWLOCs for oxyfluorfen were calculated based on anticipated residues in food alone. Surface and groundwater concentrations are substantially less than the DWLOCs for all populations. Consequently, there is no chronic aggregate concern for drinking water from surface or groundwater sources . Cancer Aggregate Cancer DWLOCs were calculated using food only and residential exposure data. The chronic food cancer risk estimate was 3.8 x 10'7
, combined with the highest residential cancer risk estimate of 8.7 x 10·7 resulted in a food+ residential cancer risk of 1.3 x 10·6

. Since USDA Pesticide Data Program (PDP) monitoring study and field trial data showed all residues on food were non-detects , the food risk estimate was considered upper-bound. Screening-level surface water modeling indicated that there may be a concern for oxyfluorfen 

### in drinking water, but thi s water modeling was also considered upper-bound. Drinking water monitoring data would allow refinement of the Estimated Drinking Water Concentrations (EDWCs)
. 

### Conclusions: In 2002 there were no chronic or short

-term aggregate (food, water and residential exposure) risk estimates of concern for oxyfluorfen. However, there appears to be a potential for oxyfluorfen residues in drinking water to occur at levels ofconcern for cancer. During Registration Review, updated aggregate asse ssments will be conducted as required to include any significant changes that might occur for toxicological PODs , FQPA and uncertainty factors , dietary expo sure estimates, EDWCs, and re sidential exposure e stimates. Emerging policies related to pesticide drift and volatilization assessments may dictate further changes to the existing aggregate risk asses sment.

Page 7 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support o f Registration R e view Occupational Exposure

Oxyfluorfen is regis te red as an herbicide for agricultural uses to control weeds in field/row crops, orchard floors , vineyard floors, and container and field grown ornamentals. Formulations include emulsifiable liquid products for agricultural use and granular p ro ducts for commercial nursery use. The last comprehensive occupationa l risk assessment was done in 2002 for the RED (Tim Do l e, D28183 1 , May 2002). There is potential for occupatio n al hand l er and postapplication exposure . Occupational Handlers The application rates for the oxyfluorfen products range from 0.25 to 2.0 l bs ai per acre per app li cat i on. Liquid formu l ations might be applied us i ng groundboom, a i rb l ast, chemigation, aerial and handheld sprayers. Aerial application is used only for fallow fields and chemigat i on i s

used primarily for bulb vegetables. Granular oxyfluorfen i s app l ied to ornamentals with broadcast spreaders . Based on the handler activity use pattern the duration of exposure was determined t o be of short (1 day to 30 days) and intermediate-term (1 to 6 months). Chron i c exposure(> 6 months) is not expected since typically only one o r t wo ap plications are made in the growing season. Reg i ste red labels require handlers to wear b ase li ne Personal Protective Equipment (PPE) (i.e., long pants, long -s leeved shirt, and shoes with socks) and chem i ca l res i s t ant g l oves . The RED addressed a ll occupational non-cancer handler scenarios . Fo r occ upationa l handlers, combined MOEs (dermal + inhalat i on) above 100 for short-term and 300 for intermed i ate-term durations do not exceed HED's l evel of concern. All short - and intermediate-term combined de r ma l and inhalation occupational exposure risk estimates for granular and l iquid formu l ations did not exceed H ED's level of concern at label required sing l e layer PPE level (i.e. , base l ine PPE

+ chemical resistant gloves). For the 2002 RED , an assessment was conducted for the carcinogenic risk estimates associated with oxyfluo r fen following exposures to occu p ationa l handlers (private and commercial; m i xers, loaders and applicators). Commercia l handlers cancer r i sk estimates we r e less than 1x10" 5 with labe l required PPE (i.e, baseline + gloves) and/or engineering controls. P riva t e growers' cancer risk estimates were l ess than 1 x 1 o- 6 at the same aforementioned level of PPE. Occupational Post - application Exposure F or the 2002 RED , post-application non - cancer and cancer oxyfluorfen agricultural exposure potent i a l risks were assessed for workers entering fields recent l y treated with oxyfluorfen to conduct tasks such as hand weeding and harvesting , shaping, scouting, irrigation, grading/tagging and thinn i ng. The restricted entry interval (RE I ) for oxyfluorfen is currently set at 24 hours for all crops except for onions, garlic and horseradish which is 48 hours . Conifer seedlings and conifer trees were 3 and 6 days, respect i vely, but in 2013 an REI amendment request was granted to reduce these t o 24 hours (D4077 5 1 , I. Nieves, April 2013 ) . Oxyfluorfen is a non-selective herbicide that can cause leaf damage to most of the labeled crops. With the exception of bulb vegetables and conifers , wh i ch have more tolerance to oxyfluorfen, over the top applications are not recommended. Therefore, it was determined that significant post-applicat i on exposure is only anticipated fo ll owing applications of oxyfluorfen to conifer Page 8 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support ofRegistration Review seedlings , conifer trees and bulb vegetables (0281831, Tim Dole, May 2002). The registrant had submitted a chemica l specific Oislodgeable Foliar Residue (DFR) study on conifers (MRID 420983-01). However, the study was found to have significant deficiencies (i.e., lack of validation data, high forti fication levels, and low recovery during the study) and new DFR data on conifers was requested by the Agency. In 2012, an oxyfluorfen DFR st udy on conif ers was submitted by Dow AgroSciences (MRID# 48895001 ) and found to be adequa te for u se in risk assessments (0405224 , I. N ieves, February 2013), ther efore no additional OFR data are necessary for conif ers. However, the Agency does not cons ider appropriate to use this chemical-specific data on bu lb vegetables because ofthe significant structura l difference in foliage between both crop s. B ased on thi s particularity, default assumptions were implemented to calculate wor kers' re-entry exposure ri sk estimates for bulb vegetables . Margins of exposure for the hand weeding activity (highest exposure scenario) did not reach the current leve l of concern of 3000 after 30 day s after treatment (MOE= 1800). Therefore, since the highest estimated occupational post-application exposure using default DFR value s is not minimal in comparison to the level of concern, EPA is requiring the 40CFR DFR data for bulb vegeta bles. Based on the Agency's current practices , a quantitative post-application inhalation exposure assessment was not performed fo r oxyfluorfen at this time primarily because of the low acute inhalation toxicity (Toxicity Category IV) , and low va por pressure of oxyfluorfen (2x 1 

## o- 7 torr at 20°C). However, there are multiple pot entia l sources of po st-application inhala tion exposure to individuals performing post-application activities in previously treated fie lds. The se potential sources include volatilization ofpesticides and resuspension of dusts and/o r particulates that contain pesticides. The Agency sought expert advice and input on issues related to vo latiliza tion of pesticides f rom its Federal Insecticide, Fungicide, and Rodenticide Act Scientific Advisory Panel (SAP) in December 2009 , and received the SAP 's final report on March 2, 2010. The Agency is in the process ofevaluating t he SAP report as well as ava ilable po st
-application inhalation exposure data generated by the ARTF and may, as appropriate, develop policies and procedures, to identify the need for and , subsequently , the way to incorporate occupational postapplication inhalation exposure into the Agency's risk assessments. If new policies or procedures are put into place, the Agency may revisit the need for a quantitative occupat ional post-application inhala tion exposure assessment for oxyfluorfen. 

### Conclusions: Previou s occupational handl er and post-application exposure assessments did not identify ri sks of concern when PPE was considered (i.e., label required chemical-resistant gloves). Registration Review will include an updated handler and post application risk estimat es based on current policies and new toxicology data (a subchroni c dermal toxicity st udy is required), and required bulb vegetables DFR data. 

### Public Health and Pesticide E p idemiology Data HED has evalua ted the available incident data6 and concludes that there doe s not appea r to be a concern at thi s time tha t would warrant further investigation, since there was .a low frequency of incidents involving oxyfluorfen reported to the OPP Incident Data System (IDS) and the Centers

6 Oxyfluorfen : Tier I Review of Human Incidents. E. Evans & Shanna Recore. July 17 , 2014. 0419420
Page 9 of20Ox y fluorfen : Human He a lth Risk Asses s ment Scopin g Document in Support of R e gi s tration Review for Disease Control and P r evention/Nationa l Institute for Occupat i onal S afety and Health (CDC/NIOSH) Sentinel Event Notification System for Occupational Risk (SENSOR)- Pesticides. The Age nc y will continue to monitor the incident informatio n and if a concern i s triggered, additional analysis will be included in the r i sk assessment. However; due to the large propo rtion of Ortho Fence & Gra s s Edger Formula II (Registration No. 239-2516) i n cidents, the Agency may evaluate this product further during the Pr e liminary Risk Assessm e nt. The Agency will continue to monitor the in c ident information and if a concern is trigger e d , additional analysis will be included in th e ri s k assessment. Tolerance Assessment and International Harmonization U.S . permanent tolerance s for residues of oxyfluorfen are established under 40 CFR § 180.381 inion a number of crop and livestock raw agricultural commodities. The tolerance expression

will need to be updated to reflect HED's Interim Guidance on Tolerance Express i ons (5 / 27/09 , S. Knizner). No maximum r e sidue limits (MRLs) for residues of o x yfluorf e n have been established by Codex or Mexico. E xcluding Canadian MRL s with no U.S. equival e nt , the remaining Canadian MRL s are fully harmonized with U . S. tolerances. See A tt achm e nt 4. Cumulative Risk Assessment Unlike other pesticides for which EPA has followed a cumulative risk approach based on a common mechanism of toxicity, EPA has not made a common mechanism of toxicity finding as to oxyfluorfen and any other subs tanc es and oxyfluorfen does not appear to produce a toxic metabolite produced by other substances. For the purposes of this toleranc e action, therefore , EPA has not assumed that oxyfluorfen has a common mechanism of tox i city with other substances. For informati o n regarding E PA ' s efforts to determine which chemicals ha v e a c ommon me c hanism o f to x icity and to evaluate the cumulat i ve effects o f s uch chemicals , see the pol i cy statement s rel e a s ed b y EPA ' s Office of Pesticide Programs conc e rning common mechanism determination s and procedures for c umulating effects f rom substances found to have a common mechani s m on EPA ' s website at http: // www.epa.gov /p esticid e s / cumulative / . Human Studies The October 2002 RED and April 2002 risk asse s sment re l ied in part on da t a from studies in which adult human s ubjects were intentionall y exposed to a pesticide to determine their dermal and inhalation expo s ure. Man y such studie s, in v ol v ing exposure t o man y different pesticide s, comprise generic pe s ticid e exposure databa s e s s uch as the P esticide Handlers E xposure D atabase (PHED), the Agricultural R eentry Task Force ( ARTF ) Database , and the Outdoor Residential Exposure Task For c e (ORETF) Database. E PA has reviewed all the studies supporting these mu l ti-pesticide generic ex p osure databases , and has found no clear and convincing evidence that the conduct of any of them was either fundamentally unethical or s i gnificant l y deficient relative

to the e thical standards prevailing at the time the research was conducte d . All applicable requirements of EPA ' s Rule for the Protection of Human Subjects o f R es e a rch ( 40 CFR Part 26) have been satisfied , and there is no regulatory barrier to continued relian c e on these studies. Page 10 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support of Registration Review 

### Risk Assessment Updates and Data Deficiencies
• A subchronic dermal rabbit toxicity study is required for oxyfluorfen (Guideline 870.3200) • Chemica l-specific DFR st udy on Bu lb Vegetables (Guideline 875.2100)

Page 

### 11 of20Oxyfluorfen: Human H ea l th Risk Assessme n t Scoping Document in Support of Registration Review References Table 1 . Memoranda Relevant to Registration Review • . A uth or Barcode Date Title Habiba, Uma TXR 0057003 TBD Oxyfluorfen: Summary of the Hazard and Science Policy Council (HASPOC) Mee t ing of June 17,20 1 4: Recommendations on the Requirement of Subchronic Dermal T oxicity Study, Acute and Subchronic Neurotoxicity Studies. Cropp- Oxyfluorfen. Cacao Bean Magnitude of the Residue D423251 08 / 07 / 2014 Data. Summary of Analytical Chemistry and Residue Kohlligian , B . Data. E. Evans and S. D419420 07117 / 2014 Oxyfluorfen: Tier I Review of Human Incidents Recore N i eves, I. D40522 4 02 / 13 / 2013 Oxyfluorfen : Dislodgeable Fo l ia r Resid ue (DFR) Study on Conifers Secondary Rev i ew Nieves , I. D407751 04 / 11 / 2013 Oxyfluorfen : Response to Amend Restricted Entry Intervals (REis) for Conifer Seedl in gs and Conifer Trees on two End-Use Product Labels. LaMay , A. D312174 09 / 04 / 2009 Oxyfluorfen : Response to Waiver Request for Dislodgeable Foliar Residue Study on Conifers . Fort, F. D281831 04 / 29 / 2002 Oxyfluorfen. Revised Human Health Risk Assessment. HED Chap ter for the Reregis tration Eligibility Decision (RED) Document. Dole, T. D28183 1 05 / 01 / 2002 Oxyfluorfen: Second Revis e d Occupationa l and Residential Non-Canc er and C ancer Expos ure and Risk Assessments for the Reregist r ation E li g ib i l ity Decision (RED) Document Kidwell, J . TXR No . 04 / 20 / 2010 Oxyfluorfen: Second Report o f t h e Cancer Assessment 0055343 Review Committee Dole , T. and D282729 04 / 30 / 2002 Oxyfluorfen: Response to Request for Waiver of Farwell , K . I nhalation T oxicity Tes t ing of Oxyfluorfen based upon exposure considerations Fort, F. 0281831 04 / 29 / 2002 Oxyfluorfen: Revised Human Health Risk Assessment. HED Chapter for the Reregistration Eligibility Decision (RED) Doc ument Fort , F. D2 76585 08 / 8 / 2001 Oxyfluorfen. Toxico l ogy Chapter for RED I . T hts table on l y mcludes references to final versiOns . PreviOus versiOns of these documents are available , but have been superseded. Page 12 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support ofRegistration Review Attachments: 

### Attachment 1 : 

### Chemical Identity and Physicochemica l Properties Attachment 2: Oxyfluorf en Acute , Subchronic, and Chronic Toxicity Profi le Attachment 3: Oxyfluorfen Toxicological Doses and Endpo ints Attachment 4: Oxyfluorfen International Resi due Limits Attachment 1. Chemical Identity and Physicochemical Properties
Table 1. Test Compound Nomenclature. Compound Chemical Structure Cl



# '-/ **CH ;**  I 11 I I

**~ ~**  

### FF

**KO~** Common name Oxyfluorfeo Empirical formula C t sH t tCIF J NO 4 IUPAC name 2-chloro- 1-(3-ethoxy

-4

-nitrophenoxy)-4-(tri fl uoromethyl)benzene CAS# 42874

-03

- 3 Table 2. Physicochemical Properties of Oxyfluorfen. Parameter Value Reference Melting ooint/range 84.5- 86 ·c pH at 2o•c 9.35 Density at 2o•c 1. 53 g/mL Water solubility ( 25 °C) 0.116 ppm Solvent solubility {mg/L at 20°C) Solvent gLL •c ethyl acetate 132 acetone 134 xylene > 250 TGA I Product Chemistry Review 1 n-octanol 10 .1 n -heptane 3.8 I ,2-dichloroet ha

ne >250 g/ kg methanol 30 Vapor pressure at 25 ° C 3 .54 x I0

- 7 torr Dissociation constant ( pKa) Does not di s sociate OctanoV water partition coeffic ie nt Log(Ko w) log Pow- 4
.468 UV / visible absorption spectrum See referenc ed me mo 1 D256409, 7 / 16/99, Harold Po dall.



### Page 

### 13 of20Oxyfluorfen : Human Heal t h Risk Assessment Scoping D ocument in Support of Reg i stration Review Attachment 2. Oxyfluorfen Acute, Subchronic, and Chronic Toxicity Profile Acute Toxicity Profile - Oxyfluorfen Guideline Study Type MRID Test Results Toxicity No. Material Category 44712010 96% LD50 > 5000 mg/kg IV 870.1 1 00 Acute Oral 4 4828903 97 . 1% LD50 > 5000 mglkg I V 447 1 2011 96% LD50 > 2000 mg/kg III 870.1200 Acute Dermal 44828904 97 . 1% LD50 > 5000 mg/kg "' 870.1300 Acute 447 1 2012 96% LC 50 > 3 . 7 I mg/L I V Inhalation Primary Eye 447 1 2013 96% s l ight irritant IV 870 . 2400 Irritation 44828906 96% ne g ative IV Primary Skin 44712014 96% slight i rritant IV 870.2500 Irritation 44828905 96% ne g ative IV Dermal 44712015 96% Negative
--- 870.2600 Sensitization 448 1 4901 23% Negative Subchronic and Chronic Toxicity Profile Guideline No. I MRID (year) I Classificatipn I Resu l ts Study Type/ % a.i . Doses INOAEL for technical no t defined LOAEL for technical = 1500 mg/kg!day based on decreased BW, increased liver wt , and mi c roscopic hepatic hypertrophy in 1/4 animals in ma l es and females 870.3200 00071915 (1978) , 92136014 . NOAEL for EC formu l ation = 24.2 mglkg/day L OAEL for 28 - day dermal Unacceptable t ech: 1500 toxicity

- rabbits mg/kg/day EC: 24.2, 96.8 EC formulation = 96 . 2 mglkg/day based on decreased B W technical75% mgfkg/day solvent control: 0.4 NOAE L for solvent control not defined EC 31.7% mL/kg!day LOAEL for solvent control= 0.4 mL / kg based on decreased BW**erma!** t oxicity occurred in all treatment groups erythema, dryness, edema) Page 14 of20· Oxyfluorfen : Human Health Risk Assessment Scoping Document in Support of Regi stration Review Subcb ronic and Chronic Toxicity Profile Guideline No. I MRID (year) I Classification I Results Study Type/% a.i. Doses p007 191 6 ( 1978), 000163582 , !NOAEL < 0.13 mg!L (M: 33.2 mglkg/day; F: 34.9 870.3465) 163584
. ron-guideline 1-

**~nacceptab e**  imglkglday

**onth** inha lation

**~.** 0 (vehicle control), 0.13, 0.65 LOAEL = 0. 13 mg/L (M: 33.2 mg/kg/day; F: 34.9 oxicity

**~gi L**  M: 33.2 and 166 .1 lmg!kg/day based on increased liver wt in low-dose fema les ,

**~3.5% ~glkg/day**  lbut not high

- dose females, lung pathology. Low-dose group 

### F: 34.9 , 174.7 mglkg/day

**~ome times**  showed more toxicity than high-dose group , many loroblerns with thi s studv .

870
.3700a

**493310 3**  ( 1997) Maternal NOAEL = I000 mglkg/day (HDT) !Developmental- rats

**~cce pt**  **able guide**  **ine** Maternal LOAEL > I000 mg/kg/day (HOT)



### ~ p, 375 , 750 , 1000 mg/ kg/day !Developmental NOAEL = 1000 mglkg/day ( HDT) !Develo pmental LOAEL > 1000 mglkg/ day (HOT )

Maternal NOAEL = 18 mg/kg/day Maternal LOAEL = 183 mglkg/day based on clinical signs red vaginal di scharge, scant f eces ).

**~7 0.3**  **700a** 141806501 (1991) lA.t 848 mglkg/ day , increase incidence of maternal mortality
. p evelopmental

- rats

**~cce ptab**  **le non-guideline**  171.4% 

## p, 18 , 183, 848 mglkg/ day Developmental NOA EL = 18 mglkg/day Developmental LOAEL = 183 mglkg/day based on increased early resorptions , decreased f etal BW , ve sse l v ariations, bent scapula, fused sternebrae , bent bone s in fore

- and hindlimb s

Maternal NOAEL = 30 mglkg/day

**~aternal** LOAEL = 90 mglkg/day based on abortions, 870
.3700b

**~4933102** (1997) linical s igns (loose feces, thin bu ild) , decreased FC, Developmental- lciecreased gravid uterine wt abbits **~cceptable non-guideline** 



### ~ 

## p , 10 , 30, 90 mglkg/day !Developmental NOAEL = 30 mglkg/ day Developmental JLOAEL = 90 mglkg/ day based on increased late resorptions , lciecreased live fetuse s/ doe

**~aterna l**  NOAEL = I0 mg/kg/day Maternal LOAEL = 30 mg/kglday based on decreased BW 870.3700b jo00940 52 ( 198 1), 00094051 , **ain** and clinical s igns (anorexia, red exudate). !Developmental

-

**~2 136018**  **,** !At 90 mglkg/day, also increased maternal mortality , abbits

**21360** 19 acceptable /guideline

**~bo rtions**  **,** hematuria, decreased motor activity 126
.9% WP jo, 0 ( vehicle), 10, 30, 90 formulation lmglkglday Deve lopmental NOAEL = 30 mg/kg/day Developmental LOAEL = 90 mg/kg/day based on decreased itter size and incr eased early resorption s



### Page 15 

### of20Oxytluorfen: Human Health Risk Assessment Scoping Docum ent in Support of Registration Review Guideline No. I IMru» (year) I !Results **~tudy** Type/ o/o a.i. lclassification I Doses !Pare ntal NOAEL = 400 ppm (M: 31; F: 33 mg/kg/day) **~2014901** (1991) IParentalLOAEL = 1600p pm(M: 120; F: 131 mg/kg/day) **~cceptable guideline**  !based on mortality , decreased BW , and liver and kidney 870.3800 p, 100 , 400 , 1600 ppm !histopathology {hepatocellular hypertrophy, renal pelvic jReproduction

- rats M : 0, 7.8, 30 . 9 , 120 !mineralization, etc) 71.4% **~g/kg/day** IF: o, 8.5 , 32.8 , 131.2 pffspr in g NOAEL = 400 ppm (M : 31; F: 33 mg/kg/day) imglk g/d ay pffspring LOAEL = 1600 ppm {M: 120; F: 131 mg / kg/day) !based on decrea sed BW /smaller litter size 00078767 (1981 ), 92136062, 92136016 870.41 OOb accep t able / guide l ine !NOAEL = 100 ppm {M: 3.1 mg/kg / day; F: 3.0 mg/kg/day) Chronic tox i city dogs p , I 00, 600, 2000 ppm I L OAEL = 600 ppm {M: 1 8.5 mg/kg/day; F: 18.8 mglkg/day) 71.4-73.8% M:0,3 . 1 , 18.5 , 61.0 !based on decreased BW gai ns , inc reas ed SAP, increased liver **~g/kg/day ~**  F: 0, 3 .0, 18.8, 60.3 imglkg/day poo83445 (1978), oot35o72, 870.4300

**~2136061** ombined chronic unacceptable jNOAEL800 / 1600 ppm (M: 56.96 mg/kg/day; F:

oxicity /

**~.** 2 , 40, 800 11 600 ppm 1 72.57 mg/kg/day) carcinoge ni city- rats M: o , o.t, 1 .94, 56.96 ILOA EL > 80011600 ppm ( M : 56.96 mg/kg/day; F: 85.7% lnglkglday

**~2.57** mg/kg/day). No t oxicity, no neoplasia F : 0 , 0.12 , 2.43, 72.57 **~g/kg/day** p0 117603 (1982, Nomura !NOAEL = 200 ppm (M: 14 mglkg/day; F: 18 870.3100 nstitute ) lmglkglday)

90-Day oral toxicity

- **~cceptable/guideline** ILOAEL = l 000 ppm (M: 71 mglkg / day; F: 75 ats p, 200, 1000, 5000 ppm lmglkg/day) based on brown livers and kidneys, 72% IM: 14, 7 1 , 361 mg/kg/day 8relative liver wt (M), 9absolute/relative thymus wt ""' : 18 , 75, 396 mg/kg/day M), liver and kidney histopathology (s l ight) 00 17602 (1982), 921360 12, 142142316 jNOAE L < 200 ppm (M: 32.0 mg/kg/day; F: 44 . 4 870.3100 acceptable /g uideline

**~0-Day** oral toxicity

- **~.** 200, 800, 3200 ppm !mglkglday !mice IM : o, 32 . o, t34.5, 490.5 p...OA EL # 200 ppm (M: 32.0 mglkg/day; F: 44.4 72.5% lmglkg/day jmg/kg/ day based on anemia 8 SGPT, 8 liver wt, liver It:-: 0, 44.4, 166 . 6 , 520 . 9 !histopathology !mglkglday **~0037939( 1977)**  **,921360 7**  INOAEL = 20 ppm (M: 3.0; F: 4 .0 mg/kg/day) LOAEL = 200 jacceptable 870.4200 P. 0 (ethanol), 2, 20,200 ppm IP pm (M: 33; F: 42 mg/k g/ day) based on increased live r wt, !Carcinogenicity mice IM: 0 , 0 (e thanol ), 0.3, 3.0 , 33 !increase d SAP and SGPT, liver histopathology (i ncluding **~7.5%** lmglkg/ d ay !hepatocyte necrosis) It:-: 0, 0 (ethanol), 0.4, 4.0, !c ombined adenomas/carcinomas i ncreased: used to set Q 1 * **~2.0** mglkg/day Page 16 of20Oxyfluorfen: Human Health Risk Assessment Scoping Document in Support o f Registration Review

**~70.7485**

**~2 37**  **20** I (1992) !Rapidly absorbed, extensively metabolized, and rapidly Metabolism and eliminated. Most compounds eliminated in the feces; females pharmacokinetics

**~265 240**  I ( 1993) e liminated more in the urine than did males. 870.7600 42142306(1989) , 92!36095 Maximal absorption= 18% at LDT when compound remaining Dermal penetration acceptable

**~n** skin is considered potentially absorbable. 4822930 I (20 I0) 870 .7 800 Acceptable /guideline

**~OAEL** = 153.5 mglkg/day. lmmunotoxjcity 0, 7.6 , 37.3 , or 153.5 fLOAEL = was not observed. mglkg/ day ABBREVIATIONS: M = Male, F = Female, BW = body weight, SAP = serum alkaline phosphatase enzyme, SGPT =serum glutamate pyru vate transaminase enzyme or ALT Hb = hemoglobin, PT = prothrombin time MFO = mixed function oxidase, EC = emulsifiable concentrate formulation, WP = wettable powder formulation LDT = lowest dose tested in study.

Page 

### 17 of20Oxyfluorfen: Human Hea lth Risk Assessment Scoping Document in Support of R egistration Review A h ttac ment 3 T . OXICO OgiCa ID oses an d E d . t n 1pom s Exposure Scenario Dose Endpoint Stud y (mglkglday) Acute Dietary An appropriate endpoint attributed to a sing l e dose was not identified. The r efo re , an acute RID was not establishe d . Li ve r toxicity occurr in g in do gs and mice at the Chronic dog study and NOAEL = 3.0 LOAEL of200 ppm in mal e (33.0 mglkg/day) and mouse carcinogenicity Chronic Dietary UF = 10 0 female ( 42.0 mg/kg/day) mice . Chronic RID = 0.03 mg / kg / day Q,*=7.32x 10 2 !Mouse carcinogenici ty Ca n ce r (mg / k g/ day) · 1 C ombined hepatoc e llul ar adenomas and ca r c i nomas. study An ap propriat e e ndpoin t a ttributed to s hort- ter m , in c i de nt al ora l exposure w as not available . Maternal effects in th e d evelop mental rabbit s tud y were n ot used becau se decreased f ood co n sum p t i on was no t Incidental O r a l , accompanied by decreased body wei g ht and clinical s i g n s i n this study were believed to be pr egnancy related , and thus not related to the population of co ncern (infants and children). The 90 - day mouse Short-Term study selecte d for the intermediate-term i n ci dental oral exposure (see be l ow), was not used because hepatic toxicity in this study is not believed to occur after 1-7 days expos ure and exposure by this short-term incidental exposure i s not expected to exceed one week in duration for oxyfluorfen . I ncidental Oral , ** LOAE L = 32 L iver to xicity and anemia seen at the LOAEL of32 90 - da y mouse c I ntermediate- Term U F = 300 mg/kg/day. Dermal* , NOAEL=30 Abortions and clinical signs see n at the maternal Developmental rabbit Sho rt- Te rm a U F = 1000 LOAEL of90 mg/kg/day study ( 1998)

D erma l * , ** LOAEL= 32 Liver toxicity and anemia seen at the LOAEL of 32 90-day mouse Intermediate- Term a U F = 3000 mglk g/ day.

Derm a l * , NOAEL = 3.0 L iv er toxicity occurrin g in d ogs and mice seen at Chr on i c dog study and L ong- T e rma UF = 1000 h e LOAEL of 18 mg/kglday in dog s and 33 in m ice. mou se carcinogenicity Inh a la t i o n , NOA EL = 30 Abort i ons and clinica l s i gns see n a t th e ma tern a l Dev e lopm en ta l rabbi t S h o rt - Termb UF = 100 LOAEL of 90 m g/kg/day. s tudy (1998) Inhalation ,** LOA E L = 32 Li ver t ox i city and anemia s e en at the LOAEL of 32 90-day mouse ln termediate-Termb UF = 300 mglk g/ day. Inhalati on , NOA EL = 3.0 Liver to xicity occurring in dogs and m ice see n at t h e Chron ic dog study and Long- Termb UF = 100 LO AEL of 18 mglkglday in dogs and 33 in mice. mouse carcinog enic i ty a. An o ral endpo mt was used for dermal exposure: dermal absorpt i on factor of 18 % of ora l exposure sha ll b e used. b. An oral endpoint was used for inhalation exposure: inhalation exposure assumed equivalent t o o r a l exposure. c. The 90 -d ay t oxicity study in rats ( 98% a . i . ) was considered for use as an en dp oint. However, t his stu dy was not selected because mice were more se n s iti ve to the old technical (71% a.i.) t h a n rats a nd no subch r onic mouse stud y wit h the 98% a . i. is available. NOAEL = no observed adverse effect level ; LOAEL =lo west observed adver se effect level *HASPOC determination s ubchron i c dermal study i s required and a I OXoa unc e rtainty factor will be r e tain e d for all d e rm al assessments u ntil this requir eme nt is fulfilled. **LOA EL to NOAEL ext rapolation a 3X fa ctor is retain ed . Page 18 of20Ox yfluorfen : Human Health Risk Assessment Scoping Document in Support of Regi st ration Review



### Attachment 4. International Residue Limits Oxyfluorfen (111601; 6 /2 3/14) Summary of US and International Tolerances and Maximum Residue Limits Residue Definition: 

## us Canada Mexico 1 Codex 40 CFR 180 .3 81 : 2-ch loro-a,a,a-tritluoro-p- None Plant/Livestock: oxytluorfen [2-chloro-1-(3

- tolyl 3-ethoxy-4-nitrophenyl ethoxy-4-n itrophenoxy)-4- ether (tritluoromethy !) benzene] Commodity Tole ran ce (ppm) !M aximum Residue Limit

**m~ kf!)**  

## us C anada Mexico 1 Codex Almond, hull s 0.1 Artichoke, globe 0.05 Avocado 0.05 Banana 0.05 Broccoli 0.05 0.05 Cabbage 0.05 0.05 Cacao bean , dried bean 0.05 Cattle, fat 0.0 1 Ca ttle , meat 0.01 Cattle, meat byproducts 0.01 Cauliflower 0.05 0.05 Coffee, b ean, green 0.05 Corn, field , grain 0.05 Cotton, undelinted seed 0
. 05 Date, dried fruit 0.05 Egg 0 .03 Feiioa 0.05 Fig 0.05 Fruit, pome, group 11 0.05 Fruit, stone, group 12 0.05 Goat, fat 0.01 Goat, meat 0.01 Goat, meat byproducts 0.0 1 Grape 0.05 Hog, fa t 0.01 Hog, meat 0.01 Hog, meat b yproducts 0
. 01 Horse , fat 0.0 1 Horse, meat 0.01 Horse , meat byproducts 0.01 Horseradi sh 0.05 Kiwifruit 0.05 Milk 0.01 N ut, tree , group 14 0.05 Olive 0.05 Onion, bulb 0.05 0.05 Peppermint, top s 0.05


### P age 

### 19 of20Oxyfluorfen: Human H ealth Risk Assessment S c o pin g Document in Support o f Registration Review S ummary of US and International T olerances and Maximum R es idue Limits Re s idue Definiti o n: us Canada Mexico 1 Codex Persimmon 0.05 Pista chi o 0.05 Pomegranate 0.05 Poultry, fat 0.2 Poultry , meat 0.01 Poultry , meat b y produ c t s 0.01

Sheep , fat 0.01 Sheep, meat 0 . 01 Sheep , meat byproduct s 0.01 Soybean 0.05 Spearm int , tops 0.05 MRLs with N o US Equivalent Brussels sprouts 0 . 05 Chinese broccol i 0 . 05 Chinese mustard cabba ges 0 . 05 Kohlrabies 0 . 05 Napa Chine se cabb ag e s 0 . 0 5 Strawberries 0.05 Comple te d: M. Negu ss ie ; 0 6 / 25 / 14 1 Mex1co ad opts US tolerances and/or Codex MRLs f o r 1t s export purposes. Tolerances with r e gional r egistr at ions . To l erances with regional registration are established for residues of the herbicide oxyfluorfen [2-chloro-1-(3-e tho xy -4- nitrophenoxy )

- 4- ( . f1 h l)b ] . h fi 11 . fi d eli . tn uoromet y enzene moron t e o owm g oo commo tles: C ommodity Parts per million Canadian MRL Blackb e rry 0 . 0 5 Chickpea, seed 0 . 05 Grass , forage 0 . 05 Grass , hay 0.05 Grass , seed screenin gs 0.05 Guava 0.0 5

Papa y a 0.0 5 Raspberry 0.05 0 . 05 Taro, corm 0.05 T a ro , leaves 0.05 Page 20 of20